See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $217B | 3.4x | 7.9x | |
| $177B | 2.8x | 7.3x | |
| $142B | 2.8x | 9.5x | |
| $97.5B | 2.3x | 6.6x | |
| $87.5B | 5.7x | 16.9x | |
| $34.5B | 4.8x | 17.9x | |
| $11.7B | n/a | n/a | |
| $8.4B | 3.1x | -6.2x | |
| $8.1B | 2.4x | 19.8x | |
| $6.2B | 13.9x | 44.3x | |
| $6.0B | 6.8x | 25.0x | |
| $5.2B | 1.9x | -1.4x | |
| $3.7B | 5.9x | 14.6x | |
| $2.8B | 7.5x | 46.2x | |
| $2.8B | 57.1x | n/a | |
| $2.6B | n/a | n/a | |
| $2.5B | 6.2x | 22.6x | |
| $2.3B | n/a | n/a | |
| $1.9B | 4.7x | 22.5x | |
| $1.9B | 2.1x | 7.1x | |
| $1.8B | 6.2x | -49.6x | |
| $1.7B | 11.6x | -19.9x | |
| $1.5B | n/a | n/a | |
| $1.2B | 6.8x | 23.9x | |
| $1.2B | n/a | n/a | |
| $1.1B | 5.8x | 8.2x | |
| $985M | 5.4x | 20.9x | |
| $919M | 6.4x | 12.9x | |
| $897M | 4.4x | 11.4x | |
| $797M | 2.7x | 21.1x | |
| $783M | 10.8x | 11.7x | |
| $774M | 4.1x | n/a | |
| $761M | 3.2x | 10.3x | |
| $662M | 0.8x | 13.2x | |
| $647M | 115.5x | -3.1x | |
| $638M | 11.7x | -30.5x | |
| $598M | 3.0x | 102.4x | |
| $584M | n/a | n/a | |
| $584M | 1.5x | 6.5x | |
| $582M | n/a | n/a | |
| $577M | n/a | -9.7x | |
| $515M | 24.0x | 157.7x | |
| $492M | 6.3x | -19.7x | |
| $488M | 453.4x | -24.0x | |
| $466M | 65.9x | -1.8x | |
| $452M | n/a | n/a | |
| $410M | 1.8x | n/a | |
| $370M | 81.0x | -20.6x | |
| $338M | 3.9x | -3.1x | |
| $328M | 1.9x | 8.6x | |
| $325M | 2.7x | 18.8x | |
| $315M | 31.8x | -1.1x | |
| $282M | n/a | n/a | |
| $280M | 1.6x | -2.7x | |
| $266M | 1.4x | 6.6x | |
| $258M | n/a | n/a | |
| $250M | 784.9x | n/a | |
| $238M | 69.4x | n/a | |
| $212M | n/a | -6.0x | |
| $208M | n/a | n/a | |
| $187M | 363.8x | n/a | |
| $182M | n/a | n/a | |
| $161M | 1.5x | n/a | |
| $152M | 6418.2x | n/a | |
| $148M | n/a | n/a | |
| $144M | n/a | n/a | |
| $137M | n/a | n/a | |
| $135M | 1.8x | 3.8x | |
| $134M | n/a | n/a | |
| $130M | n/a | n/a | |
| $123M | n/a | n/a | |
| $120M | 159.9x | n/a | |
| $107M | n/a | n/a | |
| $93.2M | 3.8x | n/a | |
| $81.5M | 3.2x | n/a | |
| $78.8M | 3.4x | -3.5x | |
| $73.3M | 35.5x | -0.7x | |
| $73.3M | 0.7x | -22.5x | |
| $70.0M | 0.3x | -0.2x | |
| $68.7M | n/a | n/a | |
| $65.7M | 0.5x | -0.8x | |
| $65.6M | 40.9x | -0.8x | |
| $64.9M | n/a | n/a | |
| $61.5M | 0.5x | -0.8x | |
| $61.0M | n/a | n/a | |
| $59.5M | 12629.2x | -2.5x | |
| $59.4M | 3218.9x | -0.2x | |
| $54.5M | 0.9x | -0.5x | |
| $53.6M | 11.9x | n/a | |
| $47.9M | n/a | -2.2x | |
| $44.4M | n/a | -0.5x | |
| $43.0M | n/a | -1.1x | |
| $42.5M | 4.8x | n/a | |
| $38.2M | n/a | n/a | |
| $36.1M | n/a | n/a | |
| $33.7M | 1.5x | n/a | |
| $29.6M | n/a | n/a | |
| $28.3M | 6.4x | n/a | |
| $25.4M | 341.0x | -0.7x | |
| $21.0M | 121.5x | n/a | |
| $19.3M | 0.3x | -0.2x | |
| $15.1M | n/a | n/a | |
| $14.8M | 5.1x | n/a | |
| $14.4M | 2.3x | -0.8x | |
| $11.9M | 0.2x | -0.0x | |
| $10.8M | 11.9x | n/a | |
| $6.9M | 0.2x | -0.0x | |
| $6.4M | n/a | n/a | |
| $2.9M | 0.1x | n/a | |
| $2.4M | 2.7x | n/a | |
| $0.5M | 0.0x | n/a | |
| -$0.6M | n/a | n/a | |
| -$2.1M | -0.3x | n/a | |
| -$5.2M | -1.0x | 0.4x | |
| -$5.8M | -0.6x | 0.0x | |
| -$6.0M | -1.8x | 0.1x | |
| -$6.1M | -3.4x | 0.0x | |
| -$17.0M | n/a | n/a | |
| -$20.1M | -0.5x | n/a | |
| -$28.2M | -4.1x | 0.2x | |
| -$28.3M | -0.2x | n/a | |
| -$31.3M | -2.2x | n/a | |
| -$37.0M | n/a | n/a | |
| -$42.3M | n/a | n/a | |
| -$42.8M | -4.8x | n/a | |
| -$49.3M | -6.2x | 1.1x | |
| -$55.3M | n/a | 0.5x | |
| -$58.2M | n/a | n/a | |
| -$62.0M | n/a | n/a | |
| -$62.9M | n/a | 0.6x | |
| -$71.5M | -15.2x | 0.6x | |
| -$74.6M | n/a | n/a | |
| -$75.2M | n/a | n/a | |
| -$102M | -690.0x | n/a | |
| -$122M | n/a | 0.8x | |
| -$131M | -6.4x | 0.9x | |
| -$133M | -2886.8x | 0.5x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies